
---
title: '康泰生物灭活新冠疫苗获批同源加强免疫接种'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=5432'
author: 证券时报网
comments: false
date: Mon, 21 Feb 2022 10:54:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=5432'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ300601" style="color: #2f67d1;text-decoration: none;" code="300601" target="_blank">康泰生物</a>消息，日前，国务院联防联控机制批准了深圳<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ300601" style="color: #2f67d1;text-decoration: none;" code="300601" target="_blank">康泰生物</a>新冠病毒灭活疫苗的同源加强免疫接种。这意味着此前全程接种<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ300601" style="color: #2f67d1;text-decoration: none;" code="300601" target="_blank">康泰生物</a>新冠病毒灭活疫苗的目标人群，可进行一剂次同源加强免疫，也就是用原疫苗进行加强。研究数据表明，同源加强免疫和序贯加强免疫都能够进一步提高免疫效果。</p>

                  
</div>
            